DoD Prostate Cancer Population-Based Research Award

The summary for the DoD Prostate Cancer Population-Based Research Award grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the Dept of the Army USAMRAA, which is the U.S. government agency offering this grant.

DoD Prostate Cancer Population-Based Research Award: The PCRP Population-Based Research Award mechanism was first offered as the Population-Based Idea Development Award in FY09. Thirty-one applications were received, and none were recommended for funding. The award mechanism has been modified for FY10. The FY10 Population-Based Research Award mechanism supports high-impact, population-based approaches to prostate cancer research. These studies, if successful, should contribute significantly to the elimination of death and suffering from prostate cancer. Proposed research must be responsive to at least one of the FY10 PCRP overarching challenges and at least one of the focus areas. The overall goal of this award is to generate unique information and/or tools that can only be achieved from the perspective of statistical analysis of a defined patient population. Applications may propose retrospective, prospective, case control, cohort, or other population-based study designs, provided the population sample is of sufficient size to demonstrate statistical significance. The study should address a well developed hypothesis that is conceptually sound and specific for prostate cancer. The statistical expertise of the study team should be clearly described and evident in the study plan. It is expected that investigators will demonstrate appropriate access to the population(s) needed for the study. Research proposed under the Population-Based Research Award may include the following areas: - Biomarkers - Predictors of response to therapy - Disease aggressiveness - Epidemiology - Genomics (germline or somatic) - Health disparity - Molecular genetics - Risk prediction Research involving human subject use is permitted under this funding opportunity, but is restricted to studies without clinical trials. In general, a clinical trial is defined as a prospective study where an intervention (e.g., device, drug, behavioral, surgical procedure, or other) is tested on human subjects for a measurable outcome. Refer to the General Application Instructions, Appendix 5, for additional information about studies involving human subjects, human subjects data, or human anatomical substances. It is the responsibility of the Principal Investigator (PI) to clearly and explicitly articulate how the project addresses the following important aspects of the Population-Based Research Award: 1. Impact: Research that has high impact will, if successful, significantly accelerate the elimination of death and suffering from prostate cancer. 2. Statistical plan: A robust statistical plan is required and should be supported with requisite statistical expertise in the study team. DOD FY10 Prostate Cancer Population-Based Research Award 4 3. Human subject plan: Applicants should provide documentation demonstrating access to, and ability to recruit, the appropriate population(s) or patient samples in numbers sufficient to achieve statistical significance. 4. Preliminary data: The presentation of preliminary data to support the study feasibility is required. Any preliminary data provided should be from the laboratory of the PI or member(s) of the collaborating team. 5. Responsiveness to PCRP overarching challenges and focus areas: The relevance of the research problem to at least one of the PCRP overarching challenges and at least one of the PCRP focus areas.